This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Dentsply International (XRAY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -500.00% and -3.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.
Dentsply International (XRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
New Strong Sell Stocks for June 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Dentsply (XRAY) Up 22.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for June 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.
Dentsply International (XRAY) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 4.88% and -0.29%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.
Earnings Preview: Dentsply International (XRAY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
First US Payroll Crash Since 2010: What's Hot, What's Not
by Sanghamitra Saha
U.S. payroll numbers in March were lackluster. We have highlighted a few industries that survived the coronavirus threat in March and also the ones that succumbed.
Dentsply (XRAY) Down 17.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.
DENTSPLY SIRONA (XRAY) Q4 Earnings Lag Estimates, Sales Rise
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from the Technologies & Equipment arm in Q4.
Dentsply International (XRAY) Q4 Earnings Lag Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -1.35% and 2.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
STERIS' (STE) Growth Picture Impressive Amid Rising Costs
by Zacks Equity Research
STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.
XRAY vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott's Alliance With Insulet to Fortify Diabetic Care Unit
by Zacks Equity Research
Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.
Integra LifeSciences Grows Organically Amid Supply Issues
by Zacks Equity Research
Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.
Integer Holdings Acquires Inomec, Extends Global Foothold
by Zacks Equity Research
Integer Holdings' (ITGR) Inomec buyout is likely to boost R&D pipeline and also strengthen and expand global foothold.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.